AI Article Synopsis
- The study analyzed the effectiveness of ceftaroline fosamil, given at a dose of 600 mg intravenously every 12 hours for 5 to 7 days, in patients with community-acquired bacterial pneumonia (CABP).
- High success rates were observed, with clinical success at 84.7% and microbiological success at 86.3%, and a majority of patients maintained drug levels above the minimum inhibitory concentration (MIC) for most of the treatment period.
- Despite these positive outcomes, the study could not identify significant pharmacokinetic-pharmacodynamic (PK-PD) relationships, but it still supports using the specified dosing regimen for treating CABP.
Article Abstract
Pharmacokinetic-pharmacodynamic (PK-PD) analyses for efficacy using phase III trial data from patients treated with a ceftaroline fosamil dosing regimen of 600 mg intravenously (i.v.) every 12 h (q12h) for 5 to 7 days for community-acquired bacterial pneumonia (CABP) were conducted. High clinical and microbiological success rates (84.7 and 86.3%, respectively) and percentages of time during the dosing interval that free-drug steady-state concentrations remained above the MIC (f%T>MIC) (98.4% had f%T>MIC values of ≥63.3) were observed among 124 microbiologically evaluable patients. As a result, significant PK-PD relationships could not be identified. These data provide support for the use of a ceftaroline fosamil dosing regimen of 600 mg i.v. q12h to treat patients with CABP.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837912 | PMC |
| http://dx.doi.org/10.1128/AAC.01748-13 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!